Osiris Therapeutics, Inc.
http://www.osiris.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Osiris Therapeutics, Inc.
Deal Watch: Innoviva To Buy The Rest Of Entasis For Enterprise Value Of $113m
Already owner of about 60% of the troubled antibiotic firm, Innoviva agrees to pay $2.20 per share for all outstanding stock in Entasis. Roche, KaliVir partner on oncolytic virus therapies.
Protagonist Weaves Positive Story From Mixed Phase II Data In Ulcerative Colitis
The company is pushing ahead into Phase III development with the lower dose of an oral drug for ulcerative colitis, even though a Phase II study missed the primary endpoint.
The Value Of Unlearning – Seen Through An Asian Medtech Innovator’s Eyes
Rising Leader Jing Lim is part of the team getting 3D implant and bone regenerating innovator Osteopore better known outside its founding base in Singapore. The company stands on the cusp of accelerated growth on the back of an expanding portfolio and its best practice approach to business building.
In Vivo’s 2022 Rising Leaders: Putting A Spotlight On Talent
The third annual listing of In Vivo’s ‘Rising Leaders’ includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.
Company Information
- Industry
- Pharmaceuticals
-
Medical Devices
- Biomaterials
- Implantable Devices
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule